US39868T1051 - Common Stock
Gritstone Bio Inc., a vaccine developer that once touted its ability to make a next-generation Covid-19 shot, filed for Chapter 11 bankruptcy in Delaware Thursday.
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA...
GRTS stock results show that Gritstone Bio beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gritstone Bio (NASDAQ:GRTS) just reported results for the second quarter of 202...
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic...
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Gritstone bio, Inc. ("Gritstone" or the "Company") (NASDAQ: GRTS) of a class action securities...
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS...
/PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gritstone bio, Inc. (NASDAQ: GRTS). Shareholders who purchased shares of GRTS...
/PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Gritstone bio, Inc. (NASDAQ: GRTS) between March 9,...